Navigation Links
BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
Date:5/3/2012

JUPITER, Fla., May 3, 2012 /PRNewswire/ -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCQB: BRTX), a life sciences company focused on adult stem cell-based therapies, announced today that the latest version of its stem cell disc delivery device, which is to be used in the treatment of bulging and herniated discs, has shown improvements when compared to earlier versions.

The first generation of the device had shown the potential to reduce disc bulges and avoid lower back surgery with a simple injection procedure.  The latest generation has shown improvements, and testing of the device will continue to be done to obtain improved disc penetration and steering for optimal cell placement. 

The patent-pending delivery device to be used by medical practitioners is a specifically designed needle/catheter delivery system that will inject cells directly into the annular tear that is causing the bulge or herniation.

On April 11, 2012, the Company announced the closing of its licensing agreement with Regenerative Sciences, Inc. pursuant to which BRT was granted, among other things, the exclusive right to license and sell the stem cell delivery device worldwide.

Mark Weinreb, CEO of BRT, commented, "The delivery device's novel design and unique capability of delivering cells, specifically where they are most effective, is a necessary component of the treatment regimen.  As our disc restoration program advances and we receive all necessary approvals, we look forward to easing the pain experienced by back and disc pain sufferers." 

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.'s goal is to become a leader in developing medical procedures using cell and tissue protocols, primarily involving a patient's own stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. The Company has obtained a license for the adult stem cell treatments of disc and spine conditions, including bulging and herniated discs. The technology is an advanced stem cell injection procedure, using the patient's own cells, that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the legs and feet.  The Company has also launched a technology that involves the use of a brown fat cell-based therapeutic/aesthetic program, known as the ThermoStem™ Program.  The ThermoStem™ Program will focus on treatments for obesity, weight loss, diabetes, hypertension, other metabolic disorders and cardiac deficiencies and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders. The Company also offers facial creams and products under the Stem Pearls® brand.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contacts:
KCSA Strategic Communications
Philip Carlson / Josh Dver
+1 212.896.1233 / +1 212.896.1239 
pcarlson@kcsa.com / jdver@kcsa.com

 


'/>"/>
SOURCE BioRestorative Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
2. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
3. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
4. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
5. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
6. BioRestorative Therapies, Inc. Begins Trading Under New Name and Symbol ("BRTX")
7. BioRestorative Therapies, Inc. Announces Upgrade to OTCQB Market
8. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
9. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
10. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
11. Steve Jobs Death Highlights Critical Need for New Therapies for Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") ... will host a Key Opinion Leader event to highlight ... oral and poster presentation at the upcoming 2017 ASCO-SITC ... KOL event will be held in-person and via live ... / 9:00 AM PST at the Lotte New York ...
(Date:2/23/2017)... Feb. 23, 2017  MIODx announced today that ... key immunotherapy technologies from the University of California, ... method to monitor a patient for response to ... CTLA-4.  The second license extends the technology with ... likely to have an immune-related adverse event (IRAE) ...
(Date:2/23/2017)... ... February 23, 2017 , ... Baltimore ... multiple immunoassay-based threat detection technologies by researchers from the Pacific National Northwest ... detection technology was found to have the best level of detection (LOD) ...
(Date:2/23/2017)... , Feb. 23, 2017 Aviva ... tools, announced the acquisition of GenWay Biotech Incorporated, ... comprehensive service and product offering for both the ... will facilitate growth and enhance capabilities for both ... and ELISA assays will nicely complement ASB,s objective ...
Breaking Biology Technology:
(Date:2/13/2017)... 13, 2017  RSA Conference -- RSA, a Dell ... designed to enhance fraud detection and investigation across ... RSA Fraud & Risk Intelligence Suite. The new ... additional insights from internal and external sources as ... their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the LEERINK Partners 6th Annual Global Healthcare ... Wednesday, February 15, 2017 at 10 a.m. Eastern Time. ... can be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Biology News(10 mins):